Nextgen Biomed Ltd (NXGN.TA)
ILA 66.8
(-0.15%)
ILA 66.8
(-0.15%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.24 Million ILS | -52.99% |
| 2022 | 2.63 Million ILS | -9.69% |
| 2021 | 2.92 Million ILS | 101.17% |
| 2020 | 1.45 Million ILS | 90.8% |
| 2019 | 761 Thousand ILS | 4.25% |
| 2018 | 730 Thousand ILS | 5.34% |
| 2017 | 693 Thousand ILS | -19.04% |
| 2016 | 856 Thousand ILS | 16.46% |
| 2015 | 735 Thousand ILS | -82.53% |
| 2014 | 4.2 Million ILS | 306.96% |
| 2013 | 1.03 Million ILS | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.88 Million ILS | 132.5% |
| 2024 Q2 | 2.88 Million ILS | 0.0% |
| 2023 Q3 | 1.24 Million ILS | -53.37% |
| 2023 Q1 | 1.32 Million ILS | -49.96% |
| 2023 FY | 1.24 Million ILS | -52.99% |
| 2023 Q2 | 2.65 Million ILS | 101.44% |
| 2023 Q4 | 1.24 Million ILS | 0.0% |
| 2022 Q2 | 3.13 Million ILS | 201.64% |
| 2022 FY | 2.63 Million ILS | -9.69% |
| 2022 Q4 | 2.63 Million ILS | 109.53% |
| 2022 Q1 | 1.03 Million ILS | -64.43% |
| 2022 Q3 | 1.25 Million ILS | -59.83% |
| 2021 Q3 | 869 Thousand ILS | -75.45% |
| 2021 Q2 | 3.54 Million ILS | 271.85% |
| 2021 Q4 | 2.92 Million ILS | 236.13% |
| 2021 Q1 | 952 Thousand ILS | -34.44% |
| 2021 FY | 2.92 Million ILS | 101.17% |
| 2020 FY | 1.45 Million ILS | 90.8% |
| 2020 Q2 | 779 Thousand ILS | 0.0% |
| 2020 Q1 | 779 Thousand ILS | 2.37% |
| 2020 Q4 | 1.45 Million ILS | 0.0% |
| 2020 Q3 | 1.45 Million ILS | 86.39% |
| 2019 Q1 | 720 Thousand ILS | -1.37% |
| 2019 Q2 | 720 Thousand ILS | 0.0% |
| 2019 Q3 | 761 Thousand ILS | 5.69% |
| 2019 Q4 | 761 Thousand ILS | 0.0% |
| 2019 FY | 761 Thousand ILS | 4.25% |
| 2018 Q2 | 864 Thousand ILS | 0.0% |
| 2018 FY | 730 Thousand ILS | 5.34% |
| 2018 Q3 | 730 Thousand ILS | -15.51% |
| 2018 Q4 | 730 Thousand ILS | 0.0% |
| 2018 Q1 | 864 Thousand ILS | 24.68% |
| 2017 Q4 | 693 Thousand ILS | 0.0% |
| 2017 FY | 693 Thousand ILS | -19.04% |
| 2017 Q1 | 883 Thousand ILS | 3.15% |
| 2017 Q3 | 693 Thousand ILS | -24.76% |
| 2017 Q2 | 921 Thousand ILS | 4.3% |
| 2016 Q1 | 813 Thousand ILS | 12.6% |
| 2016 Q2 | 796 Thousand ILS | -2.09% |
| 2016 FY | 856 Thousand ILS | 16.46% |
| 2016 Q3 | 874 Thousand ILS | 9.8% |
| 2016 Q4 | 856 Thousand ILS | -2.06% |
| 2015 Q3 | 1.14 Million ILS | -22.81% |
| 2015 Q4 | 722 Thousand ILS | -36.89% |
| 2015 Q2 | 1.48 Million ILS | 10.68% |
| 2015 Q1 | 1.33 Million ILS | -68.18% |
| 2015 FY | 735 Thousand ILS | -82.53% |
| 2014 Q4 | 4.2 Million ILS | 45.25% |
| 2014 Q2 | 1.55 Million ILS | 9.87% |
| 2014 Q3 | 2.89 Million ILS | 85.94% |
| 2014 FY | 4.2 Million ILS | 306.96% |
| 2014 Q1 | 1.41 Million ILS | 37.14% |
| 2013 Q3 | 1.27 Million ILS | 60.76% |
| 2013 Q2 | 790 Thousand ILS | 0.0% |
| 2013 Q1 | - ILS | 0.0% |
| 2013 Q4 | 1.03 Million ILS | -18.58% |
| 2013 FY | 1.03 Million ILS | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|